- •<25% of ovarian cancer patients in the U.S. receive recommended genetics services.
- •We increased the rates of genetic counseling and testing to over 85% in our clinic.
- •Various interventions were used to increase rates of genetic counseling and testing.
- •Physician-coordinated genetic testing of ovarian cancer patients is an option.
- •Genetic testing results can impact ovarian cancer treatment options.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.Cancer. 2005; 104: 2807-2816
- Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.J. Natl. Cancer Inst. 2006; 98: 1694-1706
- BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2012; 30: 2654-2663
- Meta-analysis of BRCA1 and BRCA2 penetrance.J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007; 25: 1329-1333
- Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian [Internet].National Comprehensive Cancer Network, Inc, 2008
- Society of gynecologic oncology statement on risk assessment for inherited gynecologic cancer predispositions.Gynecol. Oncol. 2015; 136: 3-7
- A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.Genet. Med. 2015; 17: 70-87
- American society of clinical oncology expert statement: collection and use of a cancer family history for oncology providers.J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2014; 32: 833-840
- Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals.Gynecol. Oncol. 2015; 138: 109-114
- Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling?.Int. J. Gynecol. Cancer. 2013; 23: 431-436
- Underuse of BRCA testing in patients with breast and ovarian cancer.Am. J. Obstet. Gynecol. 2016; 214: 761-763
- Factors associated with genetic counseling and BRCA testing in a population-based sample of young black women with breast cancer.Breast Cancer Res. Treat. 2015; 151: 169-176
- Health care segregation, physician recommendation, and racial disparities in BRCA1/2 testing among women with breast cancer.J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2016; 34: 2610-2618
- The value of a genetic counselor: improving identification of cancer genetic counseling patients with chart review.J. Genet. Couns. 2014; 23: 323-329
- Genetic testing and counseling among patients with newly diagnosed breast cancer.JAMA. 2017; 317: 531-534
- Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations.Obstet. Gynecol. 2010; 115: 945-952
- Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support.J. Biomed. Inform. 2009; 42: 377-381
- Plan-Do-Study-Act (PDSA) Cycle AHRQ.Agency for Healthcare Research and Quality: U.S. Department of Health and Human Services, 2008 ([updated 4/10/2013; cited 2017 1/25/2017]. Available from: https://innovations.ahrq.gov/qualitytools/plan-do-study-act-pdsa-cycle)
- FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy.Clin. Cancer Res. 2015; 21: 4257-4261
- The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services.Breast Cancer Res. 2014; 16
- Myriad after myriad: the proprietary data dilemma.N. C. J. Law Technol. 2014; 15: 597-637
- Preventing future cancers by testing women with ovarian cancer for BRCA mutations.J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2010; 28: 675-682
☆This project was funded by The University of Texas MD Anderson Cancer Center Breast and Ovarian Cancer Moon Shot™ Program and Phillips 66. This work was also supported by the NIH/NCI under award number P30CA016672 (used the Clinical Trials Support Resource and the Biostatistics Resource Group). Dr. Shannon Westin is supported by the Andrew Sabin Family Fellowship.